Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | End points for the next-generation bladder-sparing perioperative trials for patients with MIBC

In this latest episode of the VJOncoAlert Journal Club, Andrea Necchi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses consensus recommendations from the International Bladder Cancer Group and Global Society of Rare Genitourinary Tumors on designing perioperative trials for muscle-invasive bladder cancer (MIBC) with a focus on bladder preservation. The panel outlined standardized definitions of clinical complete response and emphasized event-free survival as the preferred primary endpoint to assess durability of benefit. The framework also highlights the importance of risk-adapted approaches and patient-centered decision-making in future bladder-sparing strategies.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.